All News
Referral Rules for At-Risk Inflammatory Arthritis
A prospective primary care study of patients at-risk for inflammatory arthritis (IA) showed that progression to IA was most likely in those with high anti-CCP antibody titers levels and involvement of the hands/feet/ IA.
Read Article
Weak Vaccine Responses in ANCA-Associated Vasculitis Patients
d
MedPage Today
Patients with ANCA-associated vasculitis (AAV) did not mount durable antibody responses to the SARS-CoV-2 Delta variant after the standard two-dose regimen of the Pfizer-BioNTech vaccine -- and for those taking rituximab (Rituxan) as maintenance therapy, even a third dose wasn't much help.
Read Article
Referral Rules for At-Risk Inflammatory Arthritis
https://t.co/p1sBNSmWF5 https://t.co/tk29UNPYdi
Links:
Dr. John Cush RheumNow ( View Tweet)
ONE MILLION DOWNLOADS!
We are excited to announce Dr.Cush and the RheumNow podcast recently hit one million downloads!
Thank you to all of our listeners-we appreciate you coming back week after week.
Find us each week where ever you get your podcasts.
https://t.co/AOJCMGZClJ https://t.co/3ImftCnqzw
Links:
Dr. John Cush RheumNow ( View Tweet)
The next generation of lupus therapies (esp in lupus nephritis) - belimumab, voclosporin , anifrolumab, obinutuzumab. Better trial designs, better organ endpoints, but yet these trials/results are limited by the high dose steroids in play.... https://t.co/48D9rI9EEH
Links:
Dr. John Cush RheumNow ( View Tweet)
How's the United States doing on boosters?
Trailing a long list of countries, including Serbia, Slovenia, and Lithuania
@OurWorldInData https://t.co/cOCVoyuqT3
Eric Topol EricTopol ( View Tweet)
UTSW Rheum Grand Rounds
New and concerning: sJIA associated lung disease - rare and associated w/ pulmonary HTN, alveolar proteinosis, high mortality. Unique features: clubbing, eosinophilia, TCZ anaphylaxis, Trisomy 21. Most were Rx w/ IL-1 > IL-6 inhibition @UTSWRheum https://t.co/aJaPurDSmJ
Dr. John Cush RheumNow ( View Tweet)
UTSW Rheum Grand Rounds - Dr. Nigrovic shows the efficacy of long acting IL-1 inhibition (canakinumab) and IL-6 (tocilizumab) in systemic JIA patients @UTSWRheum https://t.co/XdG8pAq1c4
Dr. John Cush RheumNow ( View Tweet)
UTSW Rheum Grand Rounds
Treating STill's (sJIA) - early early use of anakinra yields best results (in remission and off steroids) - 91% if Anakinra started within the first 3 mos @UTSWRheum https://t.co/neozpYhJtM
Dr. John Cush RheumNow ( View Tweet)
UTSW Rheum Grand Rounds
MAS occurs in 2-8% of Systemic JIA pts and has a high mortality (<40%); It is more frequent w/ onset in Years 1-4. Treatment - steroids, anakinra, etoposide or CsA & Rx infxn if present. Oh...dont stop the anakinra! @UTSWRheum https://t.co/09uQm3LURC
Dr. John Cush RheumNow ( View Tweet)
UTSW Rheum Grand Rounds
IL-18 levels are elevated in systemic JIA, MAS and AOSD @UTSWRheum https://t.co/pIYKf4pods
Dr. John Cush RheumNow ( View Tweet)
Dr. Peter Nigrovic asserts the division between pediatric and adult arthritis is senseless and has no firm biologic basis. Instead we should consider pts as sero- positive or negative, Systemci or Spondyloarthropathy. @UTSWRheum https://t.co/zx5oQmUQ6Y
Dr. John Cush RheumNow ( View Tweet)
van Vollenhoven et al strategies onT2T in SLE
1) Choose a Target; treat, monitor, adjust
2) LLDAS & DORIS remission are good targets
3) T2T trials needed w/ current Rx & new biologics & sm molecules
4) LLDAS & DORIS as outcomes in clinical trials
https://t.co/aTq398iaSD https://t.co/yWlp4vY7kh
Dr. John Cush RheumNow ( View Tweet)
UTSW Rheum Grand Rounds with Dr. Peter Nigrovic on systemic JIA in children and adults; yes, its the same disease with the same features. @UTSWRheum https://t.co/C7eBFjnDIi
Dr. John Cush RheumNow ( View Tweet)
Network metanalysis (28 RCTs, 12 504 pts) of Biologics & small molecules therapy in active ulcerative colitis. Upadacitinib 45 mg qd ranked 1st (RR 0.73) vs PBO, infliximab 5 mg/kg & 10 mg/kg ranked 2nd & 3rd. UPA > TNFi at remission. https://t.co/PPNkfXiJSL
Links:
Dr. John Cush RheumNow ( View Tweet)
UCB announced top-line interim analysis results from their Phase 3 "BE MOBILE 1" study, that demonstrated the efficacy of bimekizumab, a dual IL-17A and F inhibitor, in adults with active non-radiographic axial spondyloarthritis (nr-axSpA).
https://t.co/FylgQ30Dva https://t.co/XJ4y0U60hu
Links:
Dr. John Cush RheumNow ( View Tweet)
How Bad and How Far? CDC says to date, in the USA, there have been 6,715,937 COVID cases and 850,575 deaths from COVID-19. A total of 249,393,487 (75.1%) have recv at least one VAX dose, 209,312,770 (63%) fully VAX, 38.7% had a booster dose https://t.co/M9fYWL80ae
Links:
Dr. John Cush RheumNow ( View Tweet)
Using SKG mouse model of adjuvant induced SpA and enthesitis, neutrophils, and inducible IL-23, were shown to play an important role in early murine spondyloarthritis-related enthesitis. https://t.co/wlHXkNbvR7
Links:
Dr. John Cush RheumNow ( View Tweet)
192 early arthritis & 693 early arthralgia underwent the MTP-squeeze-test (MTPsqT) & MRI. Synovitis & intermetatarsal bursitis (IMB) were assoc w/ MTPsqT. In EA, MTPsqT +, 79% had synovitis or IMB: 12% synovitis, 15% IMB & 52% had both. https://t.co/Ojwb8KkmLu
Links:
Dr. John Cush RheumNow ( View Tweet)
ASK CUSH ANYTHING!
Have a Rheumatology question or case for Dr. Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology.
https://t.co/LAC6XrYEyN https://t.co/POGHk7Ibq2
Links:
Dr. John Cush RheumNow ( View Tweet)